Recruiting

kTMP

Sponsor:

Magnetic Tides

Code:

NCT07631078

Conditions

Stroke

Chronic Stroke Patients

Arm Weakness as a Consequence of Stroke

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

kTMP

Sham kTMP

Study Details

Brief summary:

kTMP, kilohertz transcutaneous magnetic perturbations, is a low intensity transcranial magnetic stimulation technique that will be used in this study to promote arm/hand rehabilitation in patients who have been disabled by stroke.

Conditions

Stroke

Chronic Stroke Patients

Arm Weakness as a Consequence of Stroke

Study ID

NCT07631078

Start date

Jul 1, 2026

Status verified date

Jul, 2026

Completion date

Aug, 2028

Anticipated

Primary completion date

Feb 28, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion criteria:

1. Adults aged 18-80 years who have a history of an ischemic or hemorrhagic stroke ≥ 12 m prior to enrollment.
2. Fugl-Meyer Assessment: Upper Extremity (FMA UE) score 20-50.
3. Ability to communicate, understand, and give appropriate consent. Participants can follow two-step commands.
4. Motor evoked potentials in a hand muscle when stimulating ipsilesional cortex with suprathreshold single-pulse TMS (MEP positive).

Exclusion criteria:

1. Participants with moderate or severe cognitive impairment (MoCA < 18).
2. Participants with sensory deficits FMA-S < 6/12 (with proprioception < 4/8).
3. Participants with severe apraxia (TULIA < 5).
4. Language impairment or behavioral disorder that interferes with their ability to adhere to the protocol or to provide informed consent.
5. Individuals who have a serious uncontrolled medical condition, including but not limited to severe cardiovascular and cardiopulmonary disease.
6. Pregnancy or plans to become pregnant during the study period.
7. Botulinum toxin injections of the affected upper extremity within 3 months prior to onset of study.
8. Severe spasticity of the affected upper limb (Modified Ashworth ≥ 4).
9. Absolute contraindications related to non-invasive brain stimulation, including:

9a) History of seizures in the last 12 months while taking anti-epilepsy medication 9b) Presence of any metal implants in the head (excluding the mouth), such as cortical stimulators and DBS, clips, coils, shunts, stents or skull plates, cochlear implants 9c) Permanent eye liner or head tattoos 9d) Implanted electronics such as pacemakers, defibrillators, intrathecal baclofen pumps or vagus nerve stimulator 9e) History of experiencing a serious adverse event during a previous transcranial magnetic stimulation (TMS) session

Study Design

Enrollment

12 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Active kTMP

Participants received 8 V/m of active stimulation

sham comparator: Sham kTMP

Participants receive sham stimulation (0.0 V/m electric field)

Interventions

kTMP

A new non-invasive brain stimulation tool

Sham kTMP

A new non-invasive brain stimulation tool with sham setting selected

Primary outcome measure

  • Range of Joint Motion (ROM) [ Time Frame: 6 weeks ]

Central Contacts and Locations

Central contacts

Locations

UCSF Mission Bay- Sandler Neurosciences Center

Recruiting

San Francisco, California, United States, 94158

Contacts

Principal Investigator:

Ludovica Labruna, PhD

More Information

Sponsor

Magnetic Tides

Last update posted

Jul 22, 2026

Last verified

Jul, 2026

Keywords

  • kTMP
  • Ischemic Stroke
  • Hemorrhagic Stroke
  • Cortical Excitability
  • Plasticity
  • kilohertz Transcranial Magnetic Perturbation
  • Cerebrovascular Disorders
  • Stroke
  • Chronic Stroke
  • Transcranial Magnetic Stimulation
  • Non-Invasive Brain Stimulation
  • Brain Disorders
  • Central Nervous System Disorders
  • Cardiovascular Disorders

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Magnetic Tides on 2026-07-22.